Neos Therapeutics, Inc. (NEOS) Financial Statements (2024 and earlier)

Company Profile

Business Address 2940 N. HIGHWAY 360
GRAND PRAIRIE, TX 75050
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2020
MRQ
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 24,89446,47850,41739,78290,763
Cash and cash equivalents 16,83046,47831,96924,35290,763
Short-term investments 8,064 18,44815,430 
Receivables 26,56327,80113,6716,1353,903
Inventory, net of allowances, customer advances and progress billings 11,01010,36713,4595,7672,520
Inventory 11,01010,36713,4595,7672,520
Other current assets  4,0325,0932,8651,058
Other undisclosed current assets 4,092  720 
Total current assets: 66,55988,67882,64055,26998,244
Noncurrent Assets
Operating lease, right-of-use asset 3,044
Property, plant and equipment 7,3457,9148,2037,0765,124
Intangible assets, net (including goodwill) 12,54314,61616,34815,57916,672
Intangible assets, net (excluding goodwill) 12,54314,61616,34815,57916,672
Other noncurrent assets 1,3821491622,2182,470
Total noncurrent assets: 24,31422,67924,71324,87324,266
TOTAL ASSETS: 90,873111,357107,35380,142122,510
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 46,83848,54822,03013,0627,965
Accounts payable 6,65012,73011,4607,7984,824
Accrued liabilities 40,18835,81810,5705,2643,141
Debt 1,5178,5578964,9217,973
Deferred revenue and credits14,6763,662 
Other undisclosed current liabilities 15,000    
Total current liabilities: 63,35557,10537,60221,64515,938
Noncurrent Liabilities
Long-term debt and lease obligation, including: 3,58543,21758,93858,59926,271
Finance lease, liability 331
Other undisclosed long-term debt and lease obligation  43,21758,93858,59926,271
Liabilities, other than long-term debt 1,2953,1902,9231,4061,380
Deferred revenue and credits1,0831,1741,166
Deferred rent credit  989
Other liabilities 160184180  
Operating lease, liability 3,254
Business combination, contingent consideration, liability    232214
Derivative instruments and hedges, liabilities 1,1352,0171,660  
Other undisclosed noncurrent liabilities 28,768  40547
Total noncurrent liabilities: 33,64846,40761,86160,04528,198
Total liabilities: 97,003103,51299,46381,69044,136
Equity
Equity, attributable to parent (6,130)7,8457,890(1,548)78,374
Common stock 5050291616
Treasury stock, value (352)(352)(352)(232)(171)
Additional paid in capital 328,056325,130274,584198,787195,314
Accumulated other comprehensive income (loss) 1 (6)(1) 
Accumulated deficit (333,885)(316,983)(266,365)(200,118)(116,785)
Total equity: (6,130)7,8457,890(1,548)78,374
TOTAL LIABILITIES AND EQUITY: 90,873111,357107,35380,142122,510

Income Statement (P&L) ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues 64,64949,98825,0189,1543,792
Revenue, net25,0189,1543,792
Cost of revenue
(Cost of Goods and Services Sold)
 (25,123)(26,928)(12,391)(11,437)(5,547)
Gross profit: 39,52623,06012,627(2,283)(1,755)
Operating expenses (49,941)(66,556)(69,643)(74,123)(24,823)
Operating loss: (10,415)(43,496)(57,016)(76,406)(26,578)
Nonoperating income
(Other Nonoperating income)
 1,5337958541,215831
Interest and debt expense (8,009)(8,974) (1,187)(576)
Loss from continuing operations before income taxes: (16,891)(51,675)(56,162)(76,378)(26,323)
Income tax expense (11)    
Loss from continuing operations: (16,902)(51,675)(56,162)(76,378)(26,323)
Loss before gain (loss) on sale of properties:(16,902)(51,675)(56,162)(76,378)(26,323)
Other undisclosed net loss   (10,085)  
Net loss: (16,902)(51,675)(66,247)(76,378)(26,323)
Other undisclosed net loss attributable to parent    (6,955)(4,458)
Net loss attributable to parent: (16,902)(51,675)(66,247)(83,333)(30,781)
Preferred stock dividends and other adjustments     (2,390)
Net loss available to common stockholders, diluted: (16,902)(51,675)(66,247)(83,333)(33,171)

Comprehensive Income ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (16,902)(51,675)(66,247)(76,378)(26,323)
Comprehensive loss: (16,902)(51,675)(66,247)(76,378)(26,323)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 16(5)(6,956) 
Comprehensive loss, net of tax, attributable to parent: (16,901)(51,669)(66,252)(83,334)(26,323)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: